Research papers and Presentation papers
GcMAF scientific & medical research
This list below is directly taken from the official US Library of Medicine (PubMed website) searching for GcMAF related studies.
- Hamilton G, Rath B, Klameth L, Hochmair MJ. Small cell lung cancer: Recruitment of macrophages by circulating tumor cells. Oncoimmunology. 2015 Oct 29;5(3):e1093277. eCollection 2016 Mar. PubMed PMID: 27141354; PubMed Central PMCID: PMC4839345.
- Delanghe JR, Speeckaert R, Speeckaert MM. Behind the scenes of vitamin D binding protein: more than vitamin D binding. Best Pract Res Clin Endocrinol Metab. 2015 Oct;29(5):773-86. doi: 10.1016/j.beem.2015.06.006. Epub 2015 Jul 2. Review. PubMed PMID: 26522461.
- Inui T, Kubo K, Kuchiike D, Uto Y, Nishikata T, Sakamoto N, Mette M. Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports. Anticancer Res. 2015 Aug;35(8):4545-9. PubMed PMID: 26168499.
- Uto Y, Kawai T, Sasaki T, Hamada K, Yamada H, Kuchiike D, Kubo K, Inui T, Mette M, Tokunaga K, Hayakawa A, Go A, Oosaki T. Degalactosylated/Desialylated Bovine Colostrum Induces Macrophage Phagocytic Activity Independently of Inflammatory Cytokine Production. Anticancer Res. 2015 Aug;35(8):4487-92. PubMed PMID: 26168491.
- Branca JJ, Morucci G, Malentacchi F, Gelmini S, Ruggiero M, Pacini S. Effects of oxaliplatin and oleic acid Gc-protein-derived macrophage-activating factor on murine and human microglia. J Neurosci Res. 2015 Sep;93(9):1364-77. doi: 10.1002/jnr.23588. Epub 2015 Mar 18. PubMed PMID: 25782915.
- Morucci G, Branca JJ, Gulisano M, Ruggiero M, Paternostro F, Pacini A, Di Cesare Mannelli L, Pacini S. Gc-protein-derived macrophage activating factor counteracts the neuronal damage induced by oxaliplatin. Anticancer Drugs. 2015 Feb;26(2):197-209. doi: 10.1097/CAD.0000000000000177. PubMed PMID: 25304987.
- Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF. Cancer Immunol Immunother. 2014 Dec;63(12):1349.
- ‘Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF)’ by Yamamoto, N., Suyama, H., Yamamoto, N. and Ushijima, N. Int J Cancer. 2014 Sep 15;135(6):1509. PubMed PMID: 25180398.
- Inui T, Makita K, Miura H, Matsuda A, Kuchiike D, Kubo K, Mette M, Uto Y, Nishikata T, Hori H, Sakamoto N. Case report: A breast cancer patient treated with GcMAF, sonodynamic therapy and hormone therapy. Anticancer Res. 2014 Aug;34(8):4589-93. Erratum in: Anticancer Res. 2015 Apr;35(4):2477. PubMed PMID: 25075104.
- Ishikawa M, Inoue T, Inui T, Kuchiike D, Kubo K, Uto Y, Nishikata T. A novel assay system for macrophage-activating factor activity using a human U937 cell line. Anticancer Res. 2014 Aug;34(8):4577-81. PubMed PMID: 25075102.
- Ruggiero M, Ward E, Smith R, Branca JJ, Noakes D, Morucci G, Taubmann M, Thyer L, Pacini S. Oleic Acid, deglycosylated vitamin D-binding protein, nitricoxide: a molecular triad made lethal to cancer. Anticancer Res. 2014 Jul;34(7):3569-78. PubMed PMID: 24982371.
- Siniscalco D, Bradstreet JJ, Cirillo A, Antonucci N. The in vitro GcMAF effects on endocannabinoid system transcriptionomics, receptor formation, and cell activity of autism-derived macrophages. J Neuroinflammation. 2014 Apr 17;11:78. doi: 10.1186/1742-2094-11-78. PubMed PMID: 24739187; PubMed Central PMCID: PMC3996516.
- Ikeda T, Kasai M, Tatsukawa E, Kamitakahara M, Shibata Y, Yokoi T, Nemoto TK, Ioku K. A bone substitute with high affinity for vitamin D-binding protein–relationship with niche of osteoclasts. J Cell Mol Med. 2014 Jan;18(1):170-80. doi: 10.1111/jcmm.12180. Epub 2013 Nov 28. PubMed PMID: 24286277; PubMed Central PMCID: PMC3916128.
- Thyer L, Ward E, Smith R, Branca JJ, Morucci G, Gulisano M, Noakes D, Eslinger R, Pacini S. GC protein-derived macrophage-activating factor decreases α-N-acetylgalactosaminidase levels in advanced cancer patients. Oncoimmunology.
- 2013 Aug 1;2(8):e25769. Epub 2013 Jul 29. PubMed PMID: 24179708; PubMed Central PMCID: PMC3812199.
- Sayegh L, Fuleihan Gel-H, Nassar AH. Vitamin D in endometriosis: a causative or confounding factor? Metabolism. 2014 Jan;63(1):32-41. doi: 10.1016/j.metabol.2013.09.012. Epub 2013 Oct 14. Review. PubMed PMID: 24135500.
The Lancet SSRN Preprints
The Effect of MAF Capsules and M Capsules on Lymphopenia and Clinical Outcomes in Non-Critical Hospitalized COVID-19 Patients (URL)
The Effect of MAF Capsules and M Capsules on Lymphopenia and Clinical Outcomes in Non-Critical Hospitalized COVID-19 Patients (URL)
US National Library of Medicine, NIH clinical trial
Trial Efficacy of Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients (SaiseiCovUKR) (URL)
The clinical trial using MAF hospitalized COVID-19 patients in Ukraine
In June 2020 we applied to the COVID-19 Scientific Technical Triage of the US FDA for the evaluation of the rationale to study the efficacy of MAF Capsules in COVID-19 treatment. The US FDA in PreIND 151946 meeting response recommended a small proof of concept (POC) study as the initial step prior to the large-scale trial be run. The US FDA indicated recommendations including the major study endpoints addressing the investigation of MAF Capsules efficacy as a potential new drug was implemented in the proposed study design. The recommended efficacy endpoints were also implemented in the open-label randomized clinical trial that started in Ukraine in November 2020 to assess the efficacy and safety of dietary supplements MAF Capsules, 148 mg and M Capsules, 148 mg in addition to standard of care (SOC) compared with SOC in the treatment of hospitalized non-critical COVID-19 patients. (PDF)
Potential role of GcMAF in suppressing the severity of COVID-19-induced immune responses: Lesson learned from HIV
The hypothesis: Based on the aforementioned findings and on documented analogies between SARS-CoV-2 and HIV, we hypothesized that the reduced conversion activity of the Gc protein (human group-specific component (Gc)) into the macrophage activating factor (MAF) could have a key role in the dysregulate immune response induced by SARS-CoV-2, just like for HIV infected patients. If this hypothesis is correct, it might help to set a valid strategy of immunotherapy also based on an off-label use of GcMAF in critically ill COVID-19 patients. (URL)
Rationales of GcMAF as a therapeutic target for SARS-CoV-2
The fact that around 96% of patients recover from the infection despite there being no antiviral therapeutics that specifically target human coronaviruses suggests that the human immune system has mechanisms to combat SARS-CoV2. (PDF)
Nature International weekly journal of science
GcMAF: our next-generation immunotherapy (PDF)
Development of colostrum MAF and its clinical application
(PDF)
Research paper
2016 Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis
ANTICANCER RESEARCH 36: 3771-3774 (2016) (PDF)
About the Sonodynamic and Photodynamic Therapy (3 papers)
[Sonodynamic and Photodynamic Therapy in Advanced Breast Carcinoma (PDF)]
Trial Efficacy of Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients (SaiseiCovUKR) (URL)
The clinical trial using MAF hospitalized COVID-19 patients in Ukraine
In June 2020 we applied to the COVID-19 Scientific Technical Triage of the US FDA for the evaluation of the rationale to study the efficacy of MAF Capsules in COVID-19 treatment. The US FDA in PreIND 151946 meeting response recommended a small proof of concept (POC) study as the initial step prior to the large-scale trial be run. The US FDA indicated recommendations including the major study endpoints addressing the investigation of MAF Capsules efficacy as a potential new drug was implemented in the proposed study design. The recommended efficacy endpoints were also implemented in the open-label randomized clinical trial that started in Ukraine in November 2020 to assess the efficacy and safety of dietary supplements MAF Capsules, 148 mg and M Capsules, 148 mg in addition to standard of care (SOC) compared with SOC in the treatment of hospitalized non-critical COVID-19 patients. (PDF)
Potential role of GcMAF in suppressing the severity of COVID-19-induced immune responses: Lesson learned from HIV
The hypothesis: Based on the aforementioned findings and on documented analogies between SARS-CoV-2 and HIV, we hypothesized that the reduced conversion activity of the Gc protein (human group-specific component (Gc)) into the macrophage activating factor (MAF) could have a key role in the dysregulate immune response induced by SARS-CoV-2, just like for HIV infected patients. If this hypothesis is correct, it might help to set a valid strategy of immunotherapy also based on an off-label use of GcMAF in critically ill COVID-19 patients. (URL)
Rationales of GcMAF as a therapeutic target for SARS-CoV-2
The fact that around 96% of patients recover from the infection despite there being no antiviral therapeutics that specifically target human coronaviruses suggests that the human immune system has mechanisms to combat SARS-CoV2. (PDF)
Nature International weekly journal of science
GcMAF: our next-generation immunotherapy (PDF)
Development of colostrum MAF and its clinical application
(PDF)
Research paper
2016 Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis
ANTICANCER RESEARCH 36: 3771-3774 (2016) (PDF)
About the Sonodynamic and Photodynamic Therapy (3 papers)
[Sonodynamic and Photodynamic Therapy in Advanced Breast Carcinoma (PDF)]
[Activated Cancer Therapy Using Light and Ultrasound – A Case Series of
Sonodynamic Photodynamic Therapy in 115 Patients over a 4 Year Period (PDF)]
Sonodynamic Photodynamic Therapy in 115 Patients over a 4 Year Period (PDF)]
[Objective Outcome Measures Following Sonodynamic Photodynamic Therapy (PDF)]
Cancer Immune Therapy in Clinic
(PDF)
Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors
(PDF)
Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis
(PDF)
Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields
(PDF)
Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports
(PDF)
Degalactosylated/Desialylated Bovine Colostrum Induces Macrophage Phagocytic Activity Independently of Inflammatory Cytokine Production
(PDF)
Establishment of a Macrophage-activating Factor Assay System Using the Human Monocytic Cell Line THP-1
(PDF)
A Novel Assay System for Macrophage-activating Factor Activity Using a Human U937 Cell Line
(PDF)
Macrophage Activation Mechanisms in Human Monocytic Cell Line-derived Macrophages
(PDF)
Case Report: A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy
(PDF)
Evaluation of the Sonosensitizing Activities of 5-Aminolevulinic Acid and Sn(IV) Chlorin e6 in Tumor-bearing Chick Embryos
(PDF)
Clinical Experience of Integrative Cancer Immunotherapy
(PDF)
Degalactosylated/Desialylated Human Serum Containing GcMAF Induces Macrophage Phagocytic Activity and In Vivo Antitumor Activity
(PDF)
GcMAF : our next generation immunotherapy
(PDF)
Clinical Experience of Integrative Cancer Immunotherapy
(PDF)
Degalactosylated/Desialylated Human Serum Containing GcMAF Induces Macrophage Phagocytic Activity and In Vivo Antitumor Activity
(URL)
Evaluation of the Sonosensitizing Activities of 5-Aminolevulinic Acid and Sn(IV) Chlorin e6 in Tumor-bearing Chick Embryos
(PDF)
Helicobacter pylori infection is associated with colon adenomatous polyps detected by high-resolution colonoscopy
(PDF)
HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer
(PDF)
Helicobacter pylori cytotoxin: A novel ligand for receptor-like protein tyrosine phosphatase ß (Review)
(URL)
Leptin treatment ameliorates anxiety in ob/ob obese mice
(URL)
Orexin reverses cholecystokinin-induced reduction in feeding
(URL)
Cancer Immune Therapy in Clinic
(PDF)
Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors
(PDF)
Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis
(PDF)
Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields
(PDF)
Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports
(PDF)
Degalactosylated/Desialylated Bovine Colostrum Induces Macrophage Phagocytic Activity Independently of Inflammatory Cytokine Production
(PDF)
Establishment of a Macrophage-activating Factor Assay System Using the Human Monocytic Cell Line THP-1
(PDF)
A Novel Assay System for Macrophage-activating Factor Activity Using a Human U937 Cell Line
(PDF)
Macrophage Activation Mechanisms in Human Monocytic Cell Line-derived Macrophages
(PDF)
Case Report: A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy
(PDF)
Evaluation of the Sonosensitizing Activities of 5-Aminolevulinic Acid and Sn(IV) Chlorin e6 in Tumor-bearing Chick Embryos
(PDF)
Clinical Experience of Integrative Cancer Immunotherapy
(PDF)
Degalactosylated/Desialylated Human Serum Containing GcMAF Induces Macrophage Phagocytic Activity and In Vivo Antitumor Activity
(PDF)
GcMAF : our next generation immunotherapy
(PDF)
Clinical Experience of Integrative Cancer Immunotherapy
(PDF)
Degalactosylated/Desialylated Human Serum Containing GcMAF Induces Macrophage Phagocytic Activity and In Vivo Antitumor Activity
(URL)
Evaluation of the Sonosensitizing Activities of 5-Aminolevulinic Acid and Sn(IV) Chlorin e6 in Tumor-bearing Chick Embryos
(PDF)
Helicobacter pylori infection is associated with colon adenomatous polyps detected by high-resolution colonoscopy
(PDF)
HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer
(PDF)
Helicobacter pylori cytotoxin: A novel ligand for receptor-like protein tyrosine phosphatase ß (Review)
(URL)
Leptin treatment ameliorates anxiety in ob/ob obese mice
(URL)
Orexin reverses cholecystokinin-induced reduction in feeding
(URL)